SXTC
China Sxt Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$2.34
−3.90%Institutional positioning
13F filings over the trailing two quarters
New 4Increased 1Reduced 0Sold out 1
| Filer | Action | Shares | Filed |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | New Position | 78,170 | May 15, 2026 |
| ROYAL BANK OF CANADA | New Position | 13 | May 15, 2026 |
| ROYAL BANK OF CANADA | Unchanged | 13 | Aug 14, 2026 |
| Caitong International Asset Management Co., Ltd | Increased | 2 | Aug 5, 2026 |
| UBS GROUP AG | New Position | 1 | May 5, 2026 |
| UBS Group AG | Unchanged | 1 | Aug 13, 2026 |
| CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | New Position | 1 | May 11, 2026 |
| SABBY MANAGEMENT, LLC | Sold Out | 0 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings